Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

‘Manual’ Labor May Boost Inhaled Remodulin’s Chances

This article was originally published in The Pink Sheet Daily

Executive Summary

United Therapeutics hopes plainer instructions will alleviate doctor and patient worry over tricky device-drug combination.
Advertisement

Related Content

FDA Approves Adcirca (Tadalafil) For PAH; United Therapeutics Ready For U.S. Launch
FDA Approves Adcirca (Tadalafil) For PAH; United Therapeutics Ready For U.S. Launch
New Drug Approvals & Regulatory Updates, In Brief
New Drug Approvals & Regulatory Updates, In Brief
Actelion Follows Innovation into GP Markets
Actelion Follows Innovation into GP Markets
NDA Submitted, MannKind’s Inhaled Insulin Faces Next Test: Finding A Partner
United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date
United Therapeutics’ Inhaled Treprostinil May Get Second Quarter 2009 Action Date
Nektar Seeking New Partner For Exubera As Pfizer Returns Rights

Topics

Advertisement
UsernamePublicRestriction

Register

PS069299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel